贝伐珠单抗联合化疗治疗晚期结直肠癌的效果观察

Efficacy of Bevacizumab Combined with Chemotherapy in the Treatment of Advanced Colorectal Cancer

目的探讨贝伐珠单抗联合化疗治疗晚期结直肠癌的效果。方法选择2012年6月至2016年3月146例晚期结直肠癌患者,随机分为两组,每组各73例。研究组患者采取贝伐珠单抗联合化疗治疗,对照组患者仅采取化疗治疗。比较两组患者的近期疗效、不良反应及远期生存情况。结果研究组患者的有效率为68.49%,获益率为91.78%,对照组的有效率为35.61%,获益率为80.82%,数据比较,差异具有统计学意义(P<0.05)。两组患者不良反应发生率比较无统计学意义(P>0.05)。研究组患者中位无进展生存时间为6.2个月(3.8~12.6个月),中位总生存时间为12.5个月(4.9~22.7个月);对照组患者中位无进展生存时间为3.2个月(2.0~9.4个月),中位总生存时间为8.4个月(3.8~20.2个月);两组数据比较,差异具有统计学意义(P<0.05)。结论晚期结直肠癌患者采用贝伐珠单抗联合化疗治疗能够显著提升疗效,延长生存期,安全有效,优于单纯化疗治疗。

Objective To investigate the effi cacy of bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer.Methods One hundred and forty-six patients with advanced colorectal cancer from June 2012 to March 2016 were randomly divided into two groups,73 patients in each group.The study group was treated with bevacizumab combined with chemotherapy,while the control group was only treated with chemotherapy.The shortterm effi cacy,adverse reactions and long-term survival of the two groups were compared.Results The eff ective rate of the study group was 68.49%,and the benefi t rate was 91.78%;the eff ective rate of the control group was 35.61%,and the benefi t rate was 80.82%,which was statistically signifi cant(P<0.05).There were no signifi cant diff erence in the incidence of adverse reactions between the two groups(P>0.05).The median progression-free survival was 6.2 months(3.8-12.6 months)and the median total survival was 12.5 months(4.9-22.7 months).In the control group,the progression-free survival time was 3.2 months(2.0-9.4 months),and the median total survival time was 8.4 months(3.8-20.2 months).The comparison was statistically signifi cant(P<0.05).Conclusions Combined treatment with bevacizumab for stageⅢcolorectal cancer patients can signifi cantly improve the effi cacy,prolong the survival period,and is safe and eff ective,better than chemotherapy alone.